Bromfenac sodium (Duract) is a phenylacetic acid-derived nonsteroidal anti-inflammatory agent introduced in the United States in 1997 and withdrawn in 1998. We describe the first case of fulminant hepatic failure associated with this agent treated successfully with liver transplantation. Similarities to hepatotoxicity with related agents is discussed.
No takes yet. Share an insight, caveat, or question.
Hunter et al. (1999) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: